Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lincoln, S.
Right arrow Articles by Farrer, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lincoln, S.
Right arrow Articles by Farrer, M.
Related Collections
Right arrow All Movement Disorders
Right arrow Parkinson's disease/Parkinsonism
Right arrow All Genetics

Neurology 2003;60:1605-1610
© 2003 American Academy of Neurology

Parkin-proven disease

Common founders but divergent phenotypes S. Lincoln, BS, J. Wiley, MD MRCPI, T. Lynch, BSc MD, MRCP, FRCPI, J. W. Langston, MD, R. Chen, PhD, A. Lang, MD, E. Rogaeva, PhD, D. S. Sa, MD, R. P. Munhoz, MD, J. Harris, PhD MS, K. Marder, MD, C. Klein, MD, G. Bisceglio, J. Hussey, BS, A. West, BS, M. Hulihan, BA, J. Hardy, PhD and M. Farrer, PhD

From the Neurogenetic Laboratories (Dr. Farrer, S. Lincoln, G. Bisceglio, J. Hussey, A. West, and M. Hulihan), Department of Neuroscience, Mayo Clinic, Jacksonville, FL; Department of Neurology (Dr. Harris), Columbia University, and Taub Institute for Research on Alzheimer’s Disease and the Aging Brain (Dr. Marder), New York; Laboratory of Neurogenetics (Dr. Hardy), National Institute on Aging, NIH, Bethesda, MD; Parkinson’s Institute (Drs. Langston and Chen), Sunnyvale, CA; Department of Neurology (Drs. Wiley and Lynch), Mater Misericordiae Hospital, University College Dublin, Ireland; Department of Medicine (Division of Neurology) (Drs. Lang, Rogaeva, Sa, and Munhoz), Toronto Western Hospital and Centre for Research in Neurodegenerative Diseases, University of Toronto, Ontario, Canada; and Department of Neurology (Dr. Klein), Medical University of Luebeck, Germany.

Address correspondence and reprint requests to Dr. M. Farrer, Genetics of Neurodegeneration, Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224; e-mail: farrer.matthew{at}mayo.edu

Objective: To compare and contrast clinical and genetic findings in six probands with parkinsonism with a parkin exon 3 438- to 477-bp deletion (Ex3{Delta}40) to search for evidence of a common founder.

Method: Clinical review, parkin gene sequencing, dosage studies, and high-resolution genotype/haplotype analysis were performed.

Results: All subjects had two or more signs consistent with a diagnosis of possible or probable PD with age at onset younger than 45 years (mean ± SD 29.3 ± 10.2 years, range 16 to 42 years). Affected individuals were either homozygotes, compound heterozygotes, or Ex3{Delta}40 carriers with one normal parkin allele. Haplotype analysis revealed both Ex3{Delta}40 and Ex7 924 C->T (R275W) mutations originated from common founders, the former most probably of Irish descent. Although three cases had Ex7 924 C->T (R275W) and Ex3{Delta}40 mutations, their clinical presentation and mode of inheritance were variable.

Conclusion: Parkin mutations on common parkin haplotypes provide testable hypotheses of parkin function in genetically defined parkinsonism.




This article has been cited by other articles:


Home page
 J ANIM SCIHome page
P. N. Thompson, J. A. P. Heesterbeek, and J. A. M. van Arendonk
Changes in disease gene frequency over time with differential genotypic fitness and various control strategies
J Anim Sci, October 1, 2006; 84(10): 2629 - 2635.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
C. Hampe, H. Ardila-Osorio, M. Fournier, A. Brice, and O. Corti
Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity
Hum. Mol. Genet., July 1, 2006; 15(13): 2059 - 2075.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
R.-M. Wu, R. Bounds, S. Lincoln, M. Hulihan, C.-H. Lin, W.-L. Hwu, J. Chen, K. Gwinn-Hardy, and M. Farrer
Parkin Mutations and Early-Onset Parkinsonism in a Taiwanese Cohort
Arch Neurol, January 1, 2005; 62(1): 82 - 87.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
R. P. Munhoz, D. S. Sa, E. Rogaeva, S. Salehi-Rad, C. Sato, H. Medeiros, M. Farrer, and A. E. Lang
Clinical Findings in a Large Family With a Parkin Ex3{Delta}40 Mutation
Arch Neurol, May 1, 2004; 61(5): 701 - 704.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
I. F. Mata, P. J. Lockhart, and M. J. Farrer
Parkin genetics: one model for Parkinson's disease
Hum. Mol. Genet., April 1, 2004; 13(90001): R127 - 133.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
M. R. Cookson, P. J. Lockhart, C. McLendon, C. O'Farrell, M. Schlossmacher, and M. J. Farrer
RING finger 1 mutations in Parkin produce altered localization of the protein
Hum. Mol. Genet., November 15, 2003; 12(22): 2957 - 2965.
[Abstract] [Full Text] [PDF]